Neurocrine Biosciences | Liquidités



Cash And Equivalent Changement Date
AbbVie USD 5.52B 1.73B 2024-12
Acadia Pharmaceuticals USD 755.99M 190.66M 2024-12
Agios Pharmaceuticals USD 76.25M 177.48M 2024-12
ALKERMES USD 291.15M 636.63M 2024-12
Alnylam Pharmaceuticals USD 966.43M 133.49M 2024-12
Amgen USD 11.97B 2.96B 2024-12
Biogen USD 2.38B 675.8M 2024-12
BioMarin Pharmaceutical USD 613.22M 324.54M 2024-12
Cytokinetics USD 94.86M 47.97M 2024-12
Dynavax Technologies USD 95.88M 23.45M 2024-12
Exelixis USD 217.37M 40.97M 2025-01
Gilead Sciences USD 7.93B 2.06B 2025-03
Halozyme Therapeutics USD 115.85M 38.47M 2024-12
Incyte USD 2.41B 720.83M 2025-03
Ionis Pharmaceuticals USD 242.08M 92.53M 2024-12
Neurocrine Biosciences USD 233M 116.1M 2024-12
Pfizer USD 1.04B 49M 2024-12
Prothena USD 471.39M 47.87M 2024-12
Regeneron Pharmaceuticals USD 3.09B 14.82B 2025-03
Repligen USD 697.23M 60.13M 2025-03
Sarepta Therapeutics USD 1.1B 905.16M 2024-12
Teva Pharmaceutical Industries USD 3.3B 19M 2024-12
Ultragenyx Pharmaceutical USD 173.73M 23.11M 2024-12
Vertex Pharmaceuticals USD 4.57B 669.6M 2024-12



Neurocrine Biosciences Liquidités - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.